Clinical Trial Update: Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of 13 weeks of GSK2881078 (a selective androgen receptor modulator) in cachexia; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia

Drugs mentioned

• GSK2881078 (GSK2881078)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cachexia | Phase 2 | Status: COMPLETED | Results posted: 2020-07-15